ストックスクリーナーアプリを入手
2.44
0.00%
0.00
アフターアワーズ：
2.43
-0.010
-0.41%
Palisade Bio Inc (PALI) 最新ニュース
Palisade Bio to Present Preclinical Results for PALI-2108 - GlobeNewswire
Brookline Capital Initiates Coverage of Palisade Bio (PALI) with Buy Recommendation - MSN
ARMISTICE CAPITAL, LLC Acquires Shares in Palisade Bio Inc - GuruFocus.com
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit - The Manila Times
Contrasting Palisade Bio (NASDAQ:PALI) & Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Palisade Bio Inc (PALI) Quarterly 10-Q Report - Quartzy
Palisade Bio Reports Third Quarter 2024 Financial Results - GlobeNewswire
Palisade Bio Advances UC Drug Trial: Key Phase 1 Milestones & Patent Wins Boost Pipeline | PALI Stock News - StockTitan
Palisade Bio initiates phase 1 study of new UC drug - Investing.com
Palisade Bio initiates phase 1 study of new UC drug By Investing.com - Investing.com Australia
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) - The Manila Times
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights - The Manila Times
Palisade Bio Announces First Subject Dosed in Phase 1 - GlobeNewswire
Palisade Bio Launches Phase 1 Trial for Novel Ulcerative Colitis Drug PALI-2108 | PALI Stock News - StockTitan
Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World
Palisade Bio advances novel IBD treatment PALI-2108 - Investing.com
Palisade Bio advances novel IBD treatment PALI-2108 By Investing.com - Investing.com UK
HYCU® Recognized as CRN 2024 Product of the Year Finalist - The Manila Times
Palisade Bio Announces Positive Data from Two Ex Vivo - GlobeNewswire
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan
PALI stock touches 52-week low at $3.09 amid market fluctuations - Investing.com
Alto Neuroscience’s depression drug trial fails at phase 2 - BioPharma-Reporter.com
Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News
Palisade Bio Announces Abstract Accepted for Presentation - GlobeNewswire
Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting - The Manila Times
Sutro Biopharma (NASDAQ:STRO) & Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast - Defense World
Meta Platforms (NASDAQ:META) Shares Up 0.6% Following Analyst Upgrade - Defense World
Palisade Bio receives Health Canada nod for UC drug trial By Investing.com - Investing.com Australia
Palisade Bio receives Health Canada nod for UC drug trial - Investing.com
Palisade Bio Cleared by Health Canada to Commence Phase 1 - GlobeNewswire
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) - Yahoo Finance
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - The Manila Times
Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews
Palisade Bio, Inc. (NASDAQ:PALI) Shares Sold by Armistice Capital LLC - Defense World
Palisade Bio inks new deal with CEO Finley; terms disclosed By Investing.com - Investing.com Canada
Palisade Bio inks new deal with CEO Finley; terms disclosed - Investing.com India
Palisade Bio CEO Finley’s Revised Employment and Compensation Deal - TipRanks
Palisade submits CTA for PDE4 inhibitor prodrug for ulcerative colitis - BioWorld Online
PALI stock touches 52-week low at $3.3 amid market fluctuations - Investing.com UK
PALIPalisade Bio, Inc. Latest Stock News & Market Updates - StockTitan
Palisade Bio Provides Update on Progress Toward Launch of - GlobeNewswire
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan
Klea Holding Evaluates Generous Takeover Offer - TipRanks
The growth track for Kura Oncology Inc (KURA) has changed recently - SETE News
Potential Price Increase for Kulicke & Soffa Industries, Inc. (KLIC) After Recent Insider Activity - Knox Daily
Big Changes At Disney Animation: Jennifer Lee Steps Down And Jared Bush Steps In - mxdwn.com
116,268 Shares in Proficient Auto Logistics, Inc. (NASDAQ:PAL) Purchased by First Eagle Investment Management LLC - MarketBeat
Angelina Jolie overwhelmed by ‘beautiful feeling’ of motherhood - FemaleFirst
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Palisade Bio (NASDAQ:PALI) Stock Quotes, Forecast and News Summary - Benzinga
Proficient Auto Logistics (NASDAQ:PAL) Earns "Outperform" Rating from Barrington Research - MarketBeat
Jared Bush Taking Over Jennifer Lee’s Role As Walt Disney Animation Studios Chief Creative Officer - What's On Disney Plus
Alaska Air completes acquisition of Hawaiian Airlines - The Seattle Times
Bokf Na Has $58,000 Stock Position in Haleon plc (NYSE:HLN) - Defense World
CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga
Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies - StockTitan
Palisade Bio Launches New Corporate Branding and Reiterates - GlobeNewswire
0.93%
3.55%
大文字化:
|
ボリューム (24 時間):